Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma

Clinical Cancer Research

Volumn 16, Issue 12, 2010, Pages 3260-3269

  Mateos, María Victoria ^a   Cibeira, Maria Teresa ^b   Richardson, Paul G ^c   Prosper, Felipe ^d   Oriol, Albert ^e   De La Rubia, Javier ^f   Lahuerta, Juan José ^g   García Sanz, Ramón ^a   Extremera, Sonia ^h   Szyldergemajn, Sergio ^h   Corrado, Claudia ^h   Singer, Harald ^h   Mitsiades, Constantine S ^c   Anderson, Kenneth C ^c   Bladé, Joan ^b   San Miguel, Jesús ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

^g HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^h PHARMAMAR S A   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLODEPSIPEPTIDE; DEXAMETHASONE; PLITIDEPSIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RELAPSE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE MYELOMA; MUSCLE ATROPHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PLASMA HALF LIFE; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEPSIPEPTIDES; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE;

EID: 77953722666     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0469     Document Type: Article

References (36)

1. Kastritis E, Mitsiades CS, Dimopoulos MA, Richardson PG. Management of relapsed and relapsed refractory myeloma. Hematol Oncol Clin North Am 2007;21:1175-215, x.
2. Anthoney A, Paz-Ares L, Twelves C, et al. Phase I and pharmacokinetic (PK) study of Aplidin (APL) using a 24-hour, weekly schedule. Proc Am Soc Clin Oncol 2000;19:Abstract #734.
3. Bowman A, Izquierdo MA, Jodrell D, et al. Phase I clinical and pharmacokinetic (PK) study of the marine compound Aplidin (APL), administered as a 1 hour weekly infusion. Proc Am Soc Clin Oncol 2001;20:Abstract 476.
4. Faivre S, Chieze S, Delbaldo C, et al. Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. J Clin Oncol 2005;23:7780-2.
5. Jimeno J, Lopez-Martin JA, Ruiz-Casado A, Izquierdo MA, Scheuer PJ, Rinehart K. Progress in the clinical development of new marine-derived anticancer compounds. Anticancer Drugs 2004;15:321-9.
6. Maroun JA, Belanger K, Seymour L, et al. Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115. Ann Oncol 2006;17:1371-8.
7. Ciruelos EM, Twelves C, Dominguez MJ, et al. Phase I clinical and pharmacokinetic study of the marine compound Aplidin (APL) administered as a 3 hour infusion every 2 weeks. Proc Am Soc Clin Oncol 2002;21:Abstract 422.
8. Gonzalez-Santiago L, Suarez Y, Zarich N, et al. Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation. Cell Death Differ 2006;13:1968-81.
9. Garcia-Fernandez LF, Losada A, Alcaide V, et al. Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C δ. Oncogene 2002;21:7533-44.
10. Cuadrado A, Gonzalez L, Suarez Y, Martinez T, Munoz A. JNK activation is critical for Aplidin-induced apoptosis. Oncogene 2004;23:4673-80.
11. Muñoz M, Alvarez E, Martinez T, et al. JNK Activation as an In Vivo Marker of Aplidin® Activity. Proceedings AACR Annual Meeting 2007:Abstract 5580.
12. Biscardi M, Caporale R, Balestri F, Gavazzi S, Jimeno J, Grossi A. VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia. Ann Oncol 2005;16:1667-74.
13. Taraboletti G, Poli M, Dossi R, et al. Antiangiogenic activity of aplidine, a new agent of marine origin. Br J Cancer 2004;90:2418-24.
14. Broggini M, Marchini SV, Galliera E, et al. Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia 2003;17:52-9.
15. Straight AM, Oakley K, Moores R, et al. Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes. Cancer Chemother Pharmacol 2006;57:7-14.
16. Depenbrock H, Peter R, Faircloth GT, Manzanares I, Jimeno J, Hanauske AR. In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells. Br J Cancer 1998;78:739-44.
17. Mitsiades CS, Ocio EM, Pandiella A, et al. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res 2008;68:5216-25.
18. Bryant J, Day R. Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics 1995;51:1372-83.
19. Ozer H, Armitage JO, Bennett CL, et al. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 2000;18:3558-85.
20. Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;20:3719-36.
21. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose of therapy and haematopoietic stem cell transplantation. Br J Haematol 1998;102:1115-23.
22. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-17.
23. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108:3458-64.
24. Richardson P, Chanan-Khan AA, Lonial S, et al. A multicenter phase 1 clinical trial of tanespimycin (KOS-953) + bortezomib (BZ):encouraging activity and manageable toxicity in heavily pre-treated patients with relapsed refractory multiple myeloma (MM). Blood 2006;108:Abstract 406.
25. Badros A, Burger AM, Philip S, et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 2009;15:5250-7.
26. Sezer O, Siegel D, San Miguel J, et al. Panobinostat and bortezomib phase I trial in multiple myeloma. Clin Lymphoma Myeloma 2009;9:Abstract 337.
27. Siegel DS, Weber DM, Mitsiades C, et al. Vorinostat/lenalidomide/ dexamethasone: a phase I study. Clin Lymphoma Myeloma 2009; 9:Abstract 241.
28. Spencer A, Lonial S, Taylor K, et al. Panobinostat and lenalidomide combination phase I trial in myeloma. Clin Lymphoma Myeloma 2009;9:Abstract 329.
29. Richardson PG, Mitsiades CS, Colson K, et al. Final results of a phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Blood 2007; 110:Abstract 1179.
30. Richardson PG, Wolf J, Jakubowiak A, et al. Phase I/II trial of perifosine + bortezomib in Rel/Ref MM patients previously treated with bortezomib. Clin Lymphoma Myeloma 2009;9:Abstract 349.
31. Jakubowiak A, Hideshima T, Sportelli P, et al. Phase I trial of perifosine, lenalidomide, and dexamethasone in relapsed or refractory myeloma. Clin Lymphoma Myeloma 2009;9:Abstract 347.
32. Rossi JF, Manges RF, Sutherland HJ, et al. Preliminary results of CNTO 328, an anti-Interleukin-6 monoclonal antibody, in combination with bortezomib in the treatment of relapsed or refractory multiple myeloma. Blood 2009;112:Abstract 867.
33. Eisen T, Thomas J, Miller WH, Jr., et al. Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma. Melanoma Res 2009;19:185-92.
34. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5.
35. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20.
36. Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P. Clinically relevant end points and new drug approvals for myeloma. Leukemia 2008;22:231-9.